Skip to content
Menu

Wells Fargo Maintains Equal-Weight on aTyr Pharma, Raises Price Target to $4

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wells Fargo analyst Derek Archila maintains aTyr Pharma (NASDAQ:ATYR) with a Equal-Weight and raises the price target from $1 to $4.

Wells Fargo analyst Derek Archila maintains aTyr Pharma (NASDAQ:ATYR) with a Equal-Weight and raises the price target from $1 to $4.

Read at benzinga.com